Robertsonian translocations (RTs) are relatively common constitutional cytogenetic abnormalities involving the acrocentric chromosomes 13, 14, 15, 21 and 22. 1 In subjects in whom RTs occur, there are no overt clinical consequences. RTs can also rarely be discovered in tumour cells obtained from some haematological malignant cases. In such cases they are acquired cytogenetic aberrations and almost always result in a trisomic karyotype that could contribute to clonal evolution of the underlying neoplastic disease. [2] [3] [4] We report a case of transplantation of haematopoietic stem cells (HSCs) bearing RTs from an apparently healthy BM donor to a recipient with AML.
A 23-year-old man was referred in February 2006 because of AML. The karyotype of BM leukaemic cells was 47,XY, þ 4. The patient underwent induction chemotherapy and CR was obtained. Cytogenetic analysis performed on BM cells in the first CR showed a normal karyotype.
In September 2006 he underwent HSC transplantation from an HLA-matched unrelated donor; HSCs were obtained from BM harvest. The conditioning regimen was BUS þ FLUDA (BU 16 mg/kg and fludarabine 120 mg/m 2 ). GVHD prophylaxis consisted of thymoglobulin, CYA and 'short-course' methotrexate. Engraftment of polymorphonuclear leukocytes 40.5 Â 10 9 /L and of platelets 420 Â 10 9 /L was reached on day þ 23. On day þ 12, the patient experienced skin and intestinal acute GVHD (Glucksberg overall grade III) that responded to 6-methylprednisolone. During the first year following transplantation, he remained in CR, as assessed by serial BM morphological examinations and by immunophenotypic analysis of BM cells. Chimerism analysis assessed at day þ 180 showed that BM cells were 97% of donor origin.
Sixteen months after BMT, an overt leukaemia relapse occurred. Treatment consisted of a course of FLA-IDA chemotherapy and a second CR was obtained. Chimerism analysis performed by DNA microsatellite (STR) on a BM sample obtained in February 2008 when the patient was in second CR showed that 100% of the cells were of donor origin. At that time, cytogenetic analysis performed on the BM showed a chromosomal abnormality, der(14;21) (q10;q10), that was different from that observed at diagnosis. The patient's second CR was consolidated by chemotherapy and subsequently by two donor lymphocyte infusions (DLIs). Three weeks after the last dose of DLI, the patient experienced severe acute GVHD of the gut that was refractory to immunosuppressive drugs and that subsequently led to his death in July 2008.
The presence in BM cells of chromosomal abnormalities that were absent at diagnosis of leukaemia, and the donor origin of BM cells observed at that time (during the second CR), suggested that the haematopoietic cells of the donor were carrying a constitutional abnormality that had been transmitted by BMT to the recipient.
We therefore performed a cytogenetic analysis on a sample of cryopreserved BM cells obtained from the donor at the time of BM harvest for transplantation. This analysis showed that the donor cells had the same abnormality observed in the patient's BM cells while he was in second remission, as the karyotype of the donor was 45,XY,-der(14;21)(q10;q10), confirming the donor origin of the abnormality found in the patient.
The incidence of inherited RTs is reported with a frequency of 1 in 1000 newborns in the general population. However, acquired RTs are also found in haematological malignancies with a frequency estimated at 1 in 300-400 patients. 4 In this case report, we describe the transmission of a constitutional RT from an unrelated, apparently healthy donor to a patient with AML who received an allogeneic BMT. The translocation found in the donor was most likely a constitutional abnormality, as it was not linked to any haematopoietic disease and was found as the only aberration.
Various types of constitutional abnormalities of the karyotype have been reported to be transmitted after BMT. Frey et al. 5 reported on an apparently healthy donor who transmitted trisomy 8. Other authors have described transmission of 45,X HSC from donors with mosaic Turner's syndrome. 6 Storb et al. 7 reported on a marrow transplant from a donor with Down's syndrome. In this case there was evidence of a clinical consequence in using these cytogenetically abnormal cells, as a good initial engraftment was followed by graft failure at day þ 70. Graze et al. 8 reported a case of a phenotypically normal donor with a t(18;22) constitutional chromosome translocation. Transmission of a constitutional RT from an HSC donor to a recipient is very rare, with only one previous case reported, that of a male patient with Ph-positive CML and constitutional Robertsonian t(14;15) who received an HLA-compatible BM from his sister who was also a carrier of Robertsonian t(14;15). 9 In this case, as in the report presented here, there were no clinical consequences for the recipient over a short observation time. Cytogenetic assay is not routinely performed on donor cells during workup before graft harvesting, and, as RTs have a frequency of 1:1000, the occurrence of transmissions of these constitutional cytogenetics from donors to recipients could be more frequent than the few published case reports would indicate. More important and potentially lethal clinical consequences for BMT recipients derive from the inability to routinely identify donors with acquired cytogenetic abnormalities in HSC before transplant, as these cytogenetic abnormalities may represent malignant diseases that are potentially transmissible to the recipient. As subclinical haematological abnormalities are more common in elderly donors, a predonation workup that includes a BM aspirate has been advised in donors of advanced age, 10 and consideration should be given to performing a cytogenetic assay as well.
In conclusion, in this case, transplantation of marrow from a donor with a balanced RT was possible and did not interfere with short-term haematopoietic engraftment. Our case report underscores that the workup of donors for suitability for HSC donation is a complex task and requires a multidisciplinary and comprehensive approach not limited solely to haematological or immunohaematological aspects.
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